Omnia Family Wealth’s Teva Pharmaceuticals TEVA Stock Holding History

Omnia Family Wealth’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-300,000	Closed	-$2.94M	–	90
2019 Q4	$2.94M	Buy	300,000 +50,000	+20%	+$446K	1.35%	17
2019 Q3	$1.72M	Buy	+250,000	New	+$1.92M	1.26%	16
2018 Q1	–	Sell	-383	Closed	-$7K	–	632
2017 Q4	$7K	Buy	383 +131	+52%	+$1.97K	﹤0.01%	312
2017 Q3	$4K	Hold	252	–	–	﹤0.01%	371
2017 Q2	$8K	Sell	252 -386	-61%	-$11.9K	﹤0.01%	326
2017 Q1	$20K	Hold	638	–	–	0.01%	212
2016 Q4	$23K	Buy	+638	New	+$25.5K	0.01%	211

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Omnia Family Wealth's TEVA Position: Q1 2020 in Review

Omnia Family Wealth sold out of Teva Pharmaceuticals (TEVA) in Q1 2020, closing a stake of 300,000 shares — an estimated $2.94M sold.

Omnia Family Wealth first reported a position in TEVA in Q4 2016 and held it in 7 quarters. The position peaked at $2.94M in Q4 2019. 459 funds tracked by Wall St. Rank hold TEVA as of Q1 2020.

Omnia Family Wealth reported no remaining Teva Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Omnia Family Wealth sold 300,000 Teva Pharmaceuticals shares in Q1 2020, an estimated $2.94M.
Omnia Family Wealth first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 7 quarters.
Omnia Family Wealth's Teva Pharmaceuticals position peaked at $2.94M in Q4 2019.
459 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2020.

Based on Omnia Family Wealth's 13F filing for Q1 2020, filed 5 May 2020.